Abstract

Hypertrophic scar (HS) is a common skin disorder characterized by excessive extracellular matrix (ECM) deposition. However, it is still unclear how the cellular composition, cell-cell communications, and crucial transcriptionally regulatory network were changed in HS. In the present study, we found that FB-1, which was identified a major type of fibroblast and had the characteristics of myofibroblast, was significantly expanded in HS by integrative analysis of the single-cell and bulk RNA sequencing (RNA-seq) data. Moreover, the proportion of KC-2, which might be a differentiated type of keratinocyte (KC), was reduced in HS. To decipher the intercellular signaling, we conducted the cell-cell communication analysis between the cell types, and found the autocrine signaling of HB-1 through COL1A1/2-CD44 and CD99-CD99 and the intercellular contacts between FB-1/FB-5 and KC-2 through COL1A1/COL1A2/COL6A1/COL6A2-SDC4. Almost all the ligands and receptors involved in the autocrine signaling of HB-1 were upregulated in HS by both scRNA-seq and bulk RNA-seq data. In contrast, the receptor of KC-2, SDC4, which could bind to multiple ligands, was downregulated in HS, suggesting that the reduced proportion of KC-2 and apoptotic phenotype of KC-2 might be associated with the downregulation of SDC4. Furthermore, we also investigated the transcriptionally regulatory network involved in HS formation. The integrative analysis of the scRNA-seq and bulk RNA-seq data identified CREB3L1 and TWIST2 as the critical TFs involved in the myofibroblast of HS. In summary, the integrative analysis of the single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data greatly improved our understanding of the biological characteristics during the HS formation.

Highlights

  • Hypertrophic scar (HS) caused by pathologically excessive collagen deposition from skin fibroblasts in the dermis and subcutis are major types of pathological scars that can be regarded as complications to abnormal wound healing (Haverstock, 2001)

  • The cell clusters included six clusters of fibroblasts (FB-1/ 2/3/4/5/6, represented by marker genes: FBLN1, COL1A1, APOE, and APCDD1), three clusters of keratinocytes (KC-1/2/3: KRT1 and KRT14), two clusters of endothelial cells (EC-1/2: THBD and SELE), T cells (TC: PTPRC), smooth muscle cells (SMC: ACTA2 and RGS5), Langerhans cells (LA: AIF1), lymphatic endothelial cells (LEC: PROX1 and PDPN), dendritic cells (DC: HLA−DRB1 and CD1C), macrophage (MP: CD68), and melanocyte (MC: MITF) (Figure 1B), suggesting that the cell types were well characterized by the marker genes

  • The differential gene expression analysis between KC-2 cells of HS and NS revealed that cell senescence or apoptosisrelated pathways such as aging, neuron death, and regulation of neuron apoptotic process were upregulated in KC-2 cells of HS (Figure 5D), suggesting that the keratinocyte apoptosis might be associated with the reduced proportion of KC-2 in HS

Read more

Summary

Introduction

Hypertrophic scar (HS) caused by pathologically excessive collagen deposition from skin fibroblasts in the dermis and subcutis are major types of pathological scars that can be regarded as complications to abnormal wound healing (Haverstock, 2001). It is found that inflammatory cells, bone marrow-derived fibrocytes, and several peptiderelated compounds may serve as essential players in hypertrophic scar development (Satoyoshi, 1966; Song et al, 2020; Wang et al, 2020) It has been well-recognized that the expressions of keratinocyte-derived interleukin-1 (IL1), tumor necrosis factor-a (TNF-a), platelet-derived growth factor (PDGF), transforming growth factor-b (TGF-b) and basic fibroblast growth factor (bFGF) are associated with extracellular matrix (ECM) remodeling, and medicines or potential reagents to prevent and treat hypertrophic scars could result in inflammatory inhibition via targeting these molecules (Limandjaja et al, 2018; Wang et al, 2020). Few hypertrophic scar animal models could perfectly reflect human skin injuries, and though much effort has been dedicated to the study of abnormal wound healing, the pathogenesis of hypertrophic scarring has not been fully unveiled, and breakthrough development in the therapeutic management for hypertrophic scars is urgently needed, as hypertrophic scarring would lead to considerable morbidity (Wang et al, 2011; Domergue et al, 2015)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call